Xiaoming Xing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoming Xing has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Huiqing Jia
Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China
6 shared publicationsYaolin Song
Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China
5 shared publicationsGuangqi Li
Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China
4 shared publicationsYang Chen
Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
4 shared publicationsHan Zhao
Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
3 shared publicationsWenwen Ran
Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, China
3 shared publications
Latest Publications
- 3 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 252
STK11 c.1062 C > G germline variant in medullary thyroid carcinoma: implications for familial predisposition and genetic counseling
- 3 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 252
STK11 c.1062 C > G germline variant in medullary thyroid carcinoma: implications for familial predisposition and genetic counseling
- Open Access
- 18 June 2026
- Published by Springer Nature in BMC Medical Education
Online learning resource preferences across learning stages: a cognitive load theory perspective in UK medical students in early years
Online learning resources (OLRs) have become an important part of the education for students in the early years of the medicine programme (Years 1–2)
- 18 June 2026
- Published by Springer Nature in BMC Medical Education
Open AccessOnline learning resource preferences across learning stages: a cognitive load theory perspective in UK medical students in early years
Online learning resources (OLRs) have become an important part of the education for students in the early years of the medicine programme (Years 1–2)
- Open Access
- 30 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Distinct mutational landscape and clonal evolution of POLE-mutated endometrial cancer: geographic variation and insights into multiple classifier status
POLE-mutated (POLEmut) endometrial cancer (EC) represents a distinct molecular subtype with a favorable prognosis. However, current knowledge is derived la
- 30 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessDistinct mutational landscape and clonal evolution of POLE-mutated endometrial cancer: geographic variation and insights into multiple classifier status
POLE-mutated (POLEmut) endometrial cancer (EC) represents a distinct molecular subtype with a favorable prognosis. However, current knowledge is derived la
- Open Access
- 8 December 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Human periodontal ligament stem cells-derived small extracellular vesicles mitigate periodontitis by regulating macrophage pyroptosis
This study aimed to investigate whether human periodontal ligament stem cells (hPDLSCs)-derived small extracellular vesicles (P-sEVs) can improve the perio
- 8 December 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessHuman periodontal ligament stem cells-derived small extracellular vesicles mitigate periodontitis by regulating macrophage pyroptosis
This study aimed to investigate whether human periodontal ligament stem cells (hPDLSCs)-derived small extracellular vesicles (P-sEVs) can improve the perio
- Open Access
- 4 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1685642
Clinical characteristics of endometrial cancers with microsatellite instability-high and BRCA1/2 mutations
Objective: The purpose of this study was to identify the clinical features of endometrial cancers (EC) with microsatellite instability-high (MSI-H) and BRCA1/2 mutations ( BRCA m). Methods: We selected patients diagnosed with EC who were MSI-H from the Affiliated Hospital of Qingdao University between March 2021 and December 2024. The clinical information was collected after applying the inclusion and exclusion criteria. Based on BRCA1/2 status, we divided the patients into two groups: the MSI-H only group (M group), and the MSI-H and BRCA m group (MB group). After comparing the clinical characteristics of the two groups, Kaplan-Meier (K-M) curves were employed to analyze the distribution of progression-free survival (PFS) between them. Finally, both univariate and multivariate Cox proportional hazards regression models were utilized to assess various prognostic variables. Results: A total of 177 patients were included in the final analysis, of whom 28 were identified as having BRCA m. The rate of laparoscopic surgery in M group was higher than that in MB group (87.25% vs. 67.86%, p -value=0.022). The lymph node metastasis rate in MB group was significantly higher than that in M group (14.29% vs. 2.01%, p -value=0.011). Additionally, a higher proportion of patients received immunotherapy in MB group (7.14% vs. 2.68%, p -value=0.011). The recurrence rates in M group and MB group were 1.34% and 17.86%, respectively ( p -value=0.003). K-M analysis indicated that there was statistically significant difference in PFS between the two groups ( p -value=0.006). Furthermore, we did not identify any independent risk factors that influenced prognosis in our study. Conclusion: The co-occurrence of BRCA m and MSI-H is associated with high rates of lymph node metastasis and recurrence. However, BRCA m was not an independent prognostic factor influencing PFS of EC with MSI-H.
- 4 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1685642
Open AccessClinical characteristics of endometrial cancers with microsatellite instability-high and BRCA1/2 mutations
Objective: The purpose of this study was to identify the clinical features of endometrial cancers (EC) with microsatellite instability-high (MSI-H) and BRCA1/2 mutations ( BRCA m). Methods: We selected patients diagnosed with EC who were MSI-H from the Affiliated Hospital of Qingdao University between March 2021 and December 2024. The clinical information was collected after applying the inclusion and exclusion criteria. Based on BRCA1/2 status, we divided the patients into two groups: the MSI-H only group (M group), and the MSI-H and BRCA m group (MB group). After comparing the clinical characteristics of the two groups, Kaplan-Meier (K-M) curves were employed to analyze the distribution of progression-free survival (PFS) between them. Finally, both univariate and multivariate Cox proportional hazards regression models were utilized to assess various prognostic variables. Results: A total of 177 patients were included in the final analysis, of whom 28 were identified as having BRCA m. The rate of laparoscopic surgery in M group was higher than that in MB group (87.25% vs. 67.86%, p -value=0.022). The lymph node metastasis rate in MB group was significantly higher than that in M group (14.29% vs. 2.01%, p -value=0.011). Additionally, a higher proportion of patients received immunotherapy in MB group (7.14% vs. 2.68%, p -value=0.011). The recurrence rates in M group and MB group were 1.34% and 17.86%, respectively ( p -value=0.003). K-M analysis indicated that there was statistically significant difference in PFS between the two groups ( p -value=0.006). Furthermore, we did not identify any independent risk factors that influenced prognosis in our study. Conclusion: The co-occurrence of BRCA m and MSI-H is associated with high rates of lymph node metastasis and recurrence. However, BRCA m was not an independent prognostic factor influencing PFS of EC with MSI-H.
- Open Access
- 1 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 120, 105954
DNA methylation mediates the immunosuppressive tumour microenvironment in metastatic endometrial clear cell carcinoma
- 1 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 120, 105954
Open AccessDNA methylation mediates the immunosuppressive tumour microenvironment in metastatic endometrial clear cell carcinoma
- Open Access
- 25 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010826
Disruption of GPSM1/CSF1 signaling reprograms tumor-associated macrophages to overcome anti-PD-1 resistance in colorectal cancer
Background Immune checkpoint blockade (ICB) therapies, particularly anti-PD-1, benefit only a limited subset of colorectal cancer (CRC) patients. G-protein signaling modulator 1 (GPSM1) is implicated in immunity and oncology, yet its role in regulating the CRC tumor microenvironment (TME) and contributing to anti-PD-1 resistance remains poorly understood. Methods We employed single-cell RNA sequencing and multiplex immunofluorescence on tumor samples from anti-PD-1-resistant CRC patients to evaluate GPSM1 expression and its impact on macrophage polarization. An orthotopic CRC xenograft model in C57BL/6 mice was used to assess the role of GPSM1 in vivo. An in vitro co-culture system, alongside mass cytometry and flow cytometry, explored GPSM1’s biological functions within the TME. We further used ChIP-PCR, mass spectrometry, and co-immunoprecipitation to elucidate the mechanisms regulating GPSM1 activity. Results GPSM1 expression was significantly elevated in anti-PD-1-resistant CRC tissues. Enhanced GPSM1 levels promoted anti-PD-1 resistance by driving macrophage polarization toward an immunosuppressive M2 phenotype, facilitating their infiltration into the TME. We identified the deubiquitinase USP9X as a key factor preventing GPSM1 degradation through K63-polyubiquitination. This stabilization of GPSM1 led to MEIS3 nuclear translocation, activating macrophage colony-stimulating factor expression. Importantly, ruxolitinib emerged as a promising GPSM1-targeting candidate, demonstrating improved efficacy in combination with anti-PD-1 therapy in both microsatellite instability-high and microsatellite stable CRC models. Conclusions Our findings highlight the pivotal role of GPSM1-driven M2 macrophage infiltration in mediating anti-PD-1 resistance in CRC. Targeting GPSM1 offers a novel therapeutic strategy to enhance ICB efficacy, potentially broadening the patient population that may benefit from these therapies.
- 25 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010826
Open AccessDisruption of GPSM1/CSF1 signaling reprograms tumor-associated macrophages to overcome anti-PD-1 resistance in colorectal cancer
Background Immune checkpoint blockade (ICB) therapies, particularly anti-PD-1, benefit only a limited subset of colorectal cancer (CRC) patients. G-protein signaling modulator 1 (GPSM1) is implicated in immunity and oncology, yet its role in regulating the CRC tumor microenvironment (TME) and contributing to anti-PD-1 resistance remains poorly understood. Methods We employed single-cell RNA sequencing and multiplex immunofluorescence on tumor samples from anti-PD-1-resistant CRC patients to evaluate GPSM1 expression and its impact on macrophage polarization. An orthotopic CRC xenograft model in C57BL/6 mice was used to assess the role of GPSM1 in vivo. An in vitro co-culture system, alongside mass cytometry and flow cytometry, explored GPSM1’s biological functions within the TME. We further used ChIP-PCR, mass spectrometry, and co-immunoprecipitation to elucidate the mechanisms regulating GPSM1 activity. Results GPSM1 expression was significantly elevated in anti-PD-1-resistant CRC tissues. Enhanced GPSM1 levels promoted anti-PD-1 resistance by driving macrophage polarization toward an immunosuppressive M2 phenotype, facilitating their infiltration into the TME. We identified the deubiquitinase USP9X as a key factor preventing GPSM1 degradation through K63-polyubiquitination. This stabilization of GPSM1 led to MEIS3 nuclear translocation, activating macrophage colony-stimulating factor expression. Importantly, ruxolitinib emerged as a promising GPSM1-targeting candidate, demonstrating improved efficacy in combination with anti-PD-1 therapy in both microsatellite instability-high and microsatellite stable CRC models. Conclusions Our findings highlight the pivotal role of GPSM1-driven M2 macrophage infiltration in mediating anti-PD-1 resistance in CRC. Targeting GPSM1 offers a novel therapeutic strategy to enhance ICB efficacy, potentially broadening the patient population that may benefit from these therapies.
- 22 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1872 (3) , 119903
GPSM1 interacts and cooperates with MMP19 to promote proliferation and EMT in colorectal cancer cells
- 22 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1872 (3) , 119903
GPSM1 interacts and cooperates with MMP19 to promote proliferation and EMT in colorectal cancer cells
- Open Access
- 15 January 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 57 (1) , 250-266
Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcomas
Purpose The genomic characteristics of uterine sarcomas have not been fully elucidated. This study aimed to explore the genomic landscape of the uterine sarcomas (USs).Materials and Methods Comprehensive genomic analysis through RNA-sequencing was conducted. Gene fusion, differentially expressed genes (DEGs), signaling pathway enrichment, immune cell infiltration, and prognosis were analyzed. A deep learning model was constructed to predict the survival of US patients.Results A total of 71 US samples were examined, including 47 endometrial stromal sarcomas (ESS), 18 uterine leiomyosarcomas (uLMS), three adenosarcomas, two carcinosarcomas, and one uterine tumor resembling an ovarian sex-cord tumor. ESS (including high-grade ESS [HGESS] and low-grade ESS [LGESS]) and uLMS showed distinct gene fusion signatures; a novel gene fusion site, MRPS18A–PDC-AS1 could be a potential diagnostic marker for the pathology differential diagnosis of uLMS and ESS; 797 and 477 uterine sarcoma DEGs (uDEGs) were identified in the ESS vs. uLMS and HGESS vs. LGESS groups, respectively. The uDEGs were enriched in multiple pathways. Fifteen genes including LAMB4 were confirmed with prognostic value in USs; immune infiltration analysis revealed the prognositic value of myeloid dendritic cells, plasmacytoid dendritic cells, natural killer cells, macrophage M1, monocytes and hematopoietic stem cells in USs; the deep learning model named Max-Mean Non-Local multi-instance learning (MMN-MIL) showed satisfactory performance in predicting the survival of US patients, with the area under the receiver operating curve curve reached 0.909 and accuracy achieved 0.804.Conclusion USs harbored distinct gene fusion characteristics and gene expression features between HGESS, LGESS, and uLMS. The MMN-MIL model could effectively predict the survival of US patients.
- 15 January 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 57 (1) , 250-266
Open AccessIntegrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcomas
Purpose The genomic characteristics of uterine sarcomas have not been fully elucidated. This study aimed to explore the genomic landscape of the uterine sarcomas (USs).Materials and Methods Comprehensive genomic analysis through RNA-sequencing was conducted. Gene fusion, differentially expressed genes (DEGs), signaling pathway enrichment, immune cell infiltration, and prognosis were analyzed. A deep learning model was constructed to predict the survival of US patients.Results A total of 71 US samples were examined, including 47 endometrial stromal sarcomas (ESS), 18 uterine leiomyosarcomas (uLMS), three adenosarcomas, two carcinosarcomas, and one uterine tumor resembling an ovarian sex-cord tumor. ESS (including high-grade ESS [HGESS] and low-grade ESS [LGESS]) and uLMS showed distinct gene fusion signatures; a novel gene fusion site, MRPS18A–PDC-AS1 could be a potential diagnostic marker for the pathology differential diagnosis of uLMS and ESS; 797 and 477 uterine sarcoma DEGs (uDEGs) were identified in the ESS vs. uLMS and HGESS vs. LGESS groups, respectively. The uDEGs were enriched in multiple pathways. Fifteen genes including LAMB4 were confirmed with prognostic value in USs; immune infiltration analysis revealed the prognositic value of myeloid dendritic cells, plasmacytoid dendritic cells, natural killer cells, macrophage M1, monocytes and hematopoietic stem cells in USs; the deep learning model named Max-Mean Non-Local multi-instance learning (MMN-MIL) showed satisfactory performance in predicting the survival of US patients, with the area under the receiver operating curve curve reached 0.909 and accuracy achieved 0.804.Conclusion USs harbored distinct gene fusion characteristics and gene expression features between HGESS, LGESS, and uLMS. The MMN-MIL model could effectively predict the survival of US patients.
- 30 August 2024
- Published by Elsevier in Academic Radiology
- Vol. 32 (1) , 134-145
An Integrated Radiopathomics Machine Learning Model to Predict Pathological Response to Preoperative Chemotherapy in Gastric Cancer
- 30 August 2024
- Published by Elsevier in Academic Radiology
- Vol. 32 (1) , 134-145
An Integrated Radiopathomics Machine Learning Model to Predict Pathological Response to Preoperative Chemotherapy in Gastric Cancer